Paper37814498
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention.
Leung E and 5 others. CPT Pharmacometrics Syst Pharmacol, 2023. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention. Papers, record 37814498. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37814498
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-HIV Agents | Major topic |
| HIV Infections | Major topic |
| Pre-Exposure Prophylaxis | Major topic |
| Female | |
| Humans | |
| Tenofovir | |
| Emtricitabine |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 AI050410 | NIAID NIH HHS | United States | P30AI050410 | PubMed and NIH | NIH RePORTER |
| T32 GM086330 | NIGMS NIH HHS | United States | T32GM086330 | PubMed and NIH | NIH RePORTER |
| 5T32GM086330 | NIGMS NIH HHS | United States | T32GM086330 | PubMed and NIH | NIH RePORTER |
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25651245 | Tenofovir-based preexposure prophylaxis for HIV infection among African women. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25651245 | PubMed |
| 2 | 15217303 | Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. | Clin Pharmacokinet | 2004 | https://conductscience.org/library/papers/15217303 | PubMed |
| 3 | 22784040 | Preexposure prophylaxis for HIV infection among African women. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22784040 | PubMed |
| 4 | 19104016 | Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. | Antimicrob Agents Chemother | 2009 | https://conductscience.org/library/papers/19104016 | PubMed |
| 5 | 22286919 | A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model. | AAPS J | 2012 | https://conductscience.org/library/papers/22286919 | PubMed |
| 6 | 22972843 | Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. | Sci Transl Med | 2012 | https://conductscience.org/library/papers/22972843 | PubMed |
| 7 | 28145472 | Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. | Sci Rep | 2017 | https://conductscience.org/library/papers/28145472 | PubMed |
| 8 | 28019088 | p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects. | CPT Pharmacometrics Syst Pharmacol | 2017 | https://conductscience.org/library/papers/28019088 | PubMed |
| 9 | 21896913 | Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. | Antimicrob Agents Chemother | 2011 | https://conductscience.org/library/papers/21896913 | PubMed |
| 10 | 25065857 | Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. | Lancet Infect Dis | 2014 | https://conductscience.org/library/papers/25065857 | PubMed |
| 11 | 24492366 | Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24492366 | PubMed |
| 12 | 25390686 | Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism. | CPT Pharmacometrics Syst Pharmacol | 2014 | https://conductscience.org/library/papers/25390686 | PubMed |
| 13 | 24203458 | Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. | J Clin Pharmacol | 2014 | https://conductscience.org/library/papers/24203458 | PubMed |
| 14 | 10843462 | Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis. | Clin Pharmacokinet | 2000 | https://conductscience.org/library/papers/10843462 | PubMed |
| 15 | 22784038 | Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22784038 | PubMed |
| 16 | 26917574 | A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. | J Infect Dis | 2016 | https://conductscience.org/library/papers/26917574 | PubMed |
| 17 | 30150483 | A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. | J Pharmacol Exp Ther | 2018 | https://conductscience.org/library/papers/30150483 | PubMed |
| 18 | 16048948 | Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/16048948 | PubMed |
| 19 | 24148552 | Pharmacokinetics and tolerability of Tenofovir disoproxil fumarate 300 mg once daily: an open-label, single- and multiple-dose study in healthy Chinese subjects. | Clin Ther | 2013 | https://conductscience.org/library/papers/24148552 | PubMed |
| 20 | 31002391 | Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen. | Clin Pharmacol Ther | 2019 | https://conductscience.org/library/papers/31002391 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42827404 | Evaluating Vaginal Microbiome Effects on Antiretroviral Exposure in the Female Genital Tract Using Pharmacometric and Machine Learning Approaches. | Clin Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42827404 | PubMed |
| 40354181 | HIV Pharmacology Data Repository: Setting the New Information-Sharing Standard for Clinical and Preclinical Pharmacokinetic Studies. | Clin Pharmacol Ther | 2025 | https://conductscience.org/library/papers/40354181 | PubMed |
| 37814498 | A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention. | CPT Pharmacometrics Syst Pharmacol | 2023 | https://conductscience.org/library/papers/37814498 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37814498
GET https://conductscience.org/api/papers/v1/37814498/references?page=2